Considering your high risk NTM population, what are the indications for systemic (IV) amikacin therapy, what are the limiting and concerning side effects, and what are the potential side effect-mitigating properties in patients with MAC lung disease?
Considering your high risk NTM population, what are the indications for systemic (IV) amikacin therapy, what are the limiting and concerning side effects, and what are the potential side effect-mitigating properties in patients with MAC lung disease?
Created by
Presenter
Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary